Implementation and Evaluation of Tailored Interventions to Increase MMR and/or HPV Vaccine
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Apr 9, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on finding ways to increase the number of people getting the HPV and MMR vaccines in underserved communities in Greece, the Netherlands, Poland, and Slovakia. The study will evaluate different strategies that address barriers to vaccination, using trusted local community members to educate parents about these vaccines. By understanding how effective these tailored interventions are, the researchers hope to improve vaccine uptake and gather information on the best ways to encourage families to vaccinate their children.
To be eligible to participate in this study, parents must have children who are eligible to receive the MMR (measles, mumps, and rubella) and/or HPV (human papillomavirus) vaccines according to their country’s guidelines. Participants will be asked to provide feedback through questionnaires to help evaluate the effectiveness of the educational sessions and strategies used. The trial is not yet recruiting participants, but it aims to gather important insights that could lead to better health outcomes for children in these communities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • parents of children eligible for MMR and/or HPV vaccination according to country guidelines on those specific vaccines
- Exclusion Criteria:
- • respondents not willing or able to fill out questionnaires
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, , Netherlands
Athens, Athene, Greece
Zielona Góra, Lubusz, Poland
Košice, Košice Region, Slovakia
Košice, , Slovakia
Patients applied
Trial Officials
Nikole Papaevgeniou, PhD
Principal Investigator
Prolepsis Institute for Preventive, Environmental and Occupational Medicine
Daniela Fiľakovská, PhD
Principal Investigator
UPJS
Maria Ganczak, MD PhD
Principal Investigator
University Zielona Gora
Michael Edelstein, MD PhD
Principal Investigator
Bar Ilan University
Cornelis Boersma, PhD
Principal Investigator
UMCG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported